Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Bullboard Posts
Post by AHybridofStreetandStocksmartson May 06, 2015 11:37pm
100 Views
Post# 23702693

Would ICO consider buying BIO?

Would ICO consider buying BIO?Biosign shareholders re-elect four directors at AGM 2015-05-06 21:09 ET - News Release Mr. Michael Gross reports BIOSIGN ANNOUNCES RESULTS OF SHAREHOLDERS MEETING Biosign Technologies Inc. held an annual and special meeting of shareholders on May 5, 2015, where all of the items of business of the company were approved, including: To re-elect the board of directors, consisting of Dr. Michael Gross, Dennis Rygwalski, Brian Neill and Ron Kelusky; To appoint Collins Barrow Toronto LLP, chartered accountants, as auditor of the company until the next annual meeting of shareholders or until a successor is appointed at a remuneration to be approved by the board of directors of the corporation; To reapprove the company's rolling 10-per-cent stock option plan; To authorize the company to make an application to be continued under the Canada Business Corporations Act; To change the province of the registered office of the corporation from Ontario to Nova Scotia; To authorize an amendment to the articles of the corporation to consolidate the outstanding common shares of the corporation on an up-to-one-new-common-share-for-10-old-common-share basis, with the directors being authorized to determine the final consolidation basis within such range.
Bullboard Posts